- Home
- ARHS vs RGNX Comparison
ARHS vs RGNX Comparison
Compare ARHS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | RGNX |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 793.5M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARHS | RGNX |
|---|---|---|
| Price | $9.35 | $10.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $10.78 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,379,222,000.00 | $10,393,000.00 |
| Revenue This Year | $7.23 | $51.21 |
| Revenue Next Year | $7.10 | $19.08 |
| P/E Ratio | $32.17 | ★ N/A |
| Revenue Growth | 8.51 | ★ 126.48 |
| 52 Week Low | $5.57 | $5.46 |
| 52 Week High | $12.19 | $16.19 |
Technical Indicators
Market Signals| Indicator | ARHS | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 48.84 |
| Support Level | $7.28 | $7.95 |
| Resistance Level | $11.39 | $11.17 |
| Average True Range (ATR) | 0.58 | 0.68 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 62.60 | 34.08 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.